132results about How to "Increase infectivity" patented technology

Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian eye. Also disclosed are methods for intravitreal delivery of therapeutic gene constructs to retinal neuron cells, and specifically to ON bipolar cells, of the mammalian eye, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and / or in vivo applications including the treatment of retinitis pigmentosa, melanoma-associated retinopathy, and congenital stationary night blindness.

Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. μ˜500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4×1013 vg / mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.

The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously, tumour volume regressions are obtained. Therefore the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.

The invention belongs to the technical field of biological control of pests and relates to a Lecanicillium lecanii and application of the Lecanicillium lecanii to control of greenhouse pests. The strain is Lecanicillium lecanii, is preserved in CGMCC (China General Microbiological Culture Collection Center) with the preservation number CGMCC No.8453, can be used for controlling greenhouse pests like whiteflies, aphids and thrips, and can be used in pollution-free vegetable and green food vegetable production greenhouses.

The invention discloses culture media for edible mycorrhizal fungi and symbiotic seedlingsand and a synchronous culture method by utilizing the culture media. The culture media for the edible mycorrhizal fungi and the symbiotic seedlings comprise an edible mycorrhizal fungus strain mycelium culture medium and an edible mycorrhizal fungus symbiosis seedling synthesis culture medium, and the ediblemycorrhizal fungus strain mycelium culture medium includes a solid culture medium used for expanding reproduction of the mycelium and a liquid culture medium used for culturing mycelium which is usedfor inoculation of the mycorrhizal symbiotic seedlings. The synchronous culture method for implementing edible mycorrhizal fungus symbiotic seedling synthesis by utilizing the above culture media comprises the following steps: (1) a cultivation method for the edible mycorrhizal fungus strain mycelium, (2) a cultivation method for the edible mycorrhizal fungus symbiotic seedlings. According to theinvention, cultivation of the edible mycorrhizal fungus mycelium is divided into two stages including solid culture and liquid culture, liquid fungus strains are adopted for inoculation, and meanwhilethe edible mycorrhizal fungus mycelium and symbiotic plants in the mycorrhizal seedling synthesis culture medium grow together, so that the infection ability of the mycelium is increased by 30% or more, the success rate of the inoculation is increased by 20%-30%, and the survival rates of symbiotic plant seedlings and the mycorrhizal fungus mycelium are both increased by 20% or more.

The invention relates to phage lyase composite powder. The composite powder composition comprises the following components in percentage by mass: 0.15%-0.2% of phage lyase TSPpgh, 0.15%-0.2% of phagelyase MMPpgh, 0.3%-0.5% of trehalose, 0.1%-0.2% of citric acid, 0.2%-0.3% of mannitol, 0.2%-0.3% of vitamin C and 98.3%-98.9% of diatomite. The phage lyase composite powder is subjected to in-vitro antibacterial activity detection by adopting a two layer plating method. After the composite powder is stored for 12 months at normal temperature, the enzyme activity is kept at 95% or above (the enzymeactivity loss is within 5%). The composite lyase preparation can be used for replacing antibiotics to inhibit proliferation of harmful pathogenic bacteria such as escherichia coli, salmonella and staphylococcus aureus in animal intestines, and can maintain intestinal microecological balance.

The invention provides a method for conjugating a peptide displayed on a genetic display system to a molecular scaffold performed on an ion exchange resin.

A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.